{"id":3852,"date":"2025-03-31T18:11:51","date_gmt":"2025-03-31T18:11:51","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/clomipramine-hydrochloride-txt\/"},"modified":"2025-03-31T18:11:51","modified_gmt":"2025-03-31T18:11:51","slug":"clomipramine-hydrochloride-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/clomipramine-hydrochloride-txt\/","title":{"rendered":"Clomipramine hydrochloride.txt"},"content":{"rendered":"

Clomipramine hydrochloride<\/h1>\n

CLINICAL USE <\/H3>
\nDepressive illness Phobic and obsessional states Adjunctive treatment of cataplexy associated with narcolepsy

DOSE IN NORMAL RENAL FUNCTION <\/H3>10\u2013250 mg dailyCataplexy: 10\u201375 mg daily

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :351.3<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :97.6<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 2<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :12\u201317<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :12\u201336\/\u2013

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Start at lower doses and increase according to response
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Start at lower doses and increase according to response

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR <10 mL\/min <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR=10\u201320 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsAlcohol: increased sedative effect Analgesics: increased risk of CNS toxicity with tramadol; possibly increased risk of side effects with nefopam; possibly increased sedative effects with opioidsAnti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone \u2013 avoid concomitant use; increased risk of ventricular arrhythmias with drugs that prolong the QT interval; increased risk of arrhythmias with propafenoneAntibacterials: increased risk of ventricular arrhythmias with moxifloxacin \u2013 avoid concomitant use; concentration possibly reduced by rifampicinAnticoagulants: may alter anticoagulant effect of coumarinsAntidepressants: possibly increased serotonergic effects with duloxetine; enhanced CNS excitation and hypertension with MAOIs and moclobemide; concentration possibly increased with SSRIsAnti-epileptics: convulsive threshold lowered; concentration reduced by carbamazepine, primidone, barbiturates and possibly phenytoinAntimalarials: avoid concomitant use with artemether\/lumefantrineAntipsychotics: increased risk of ventricular arrhythmias especially with pimozide; increased antimuscarinic effects with clozapine and phenothiazines; concentration increased by antipsychoticsAntivirals: increased tricyclic side effects with amprenavir; concentration possibly increased with ritonavirAtomoxetine: increased risk of ventricular arrhythmias and possibly convulsionsBeta-blockers: increased risk of ventricular arrhythmias with sotalolClonidine: tricyclics antagonise hypotensive effect; increased risk of hypertension on clonidine withdrawalDopaminergics: avoid use with entacapone; CNS toxicity reported with selegiline and rasagilinePentamidine: increased risk of ventricular arrhythmiasSibutramine: increased risk of CNS toxicity \u2013 avoid concomitant use. Sympathomimetics: increased risk of hypertension and arrhythmias with adrenaline and noradrenaline; metabolism possibly inhibited by methylphenidateClomipramine hydrochloride.

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>Normal doses have been used in dialysis patients long term, but caution as parent drug and active metabolites may accumulate
    \n","protected":false},"excerpt":{"rendered":"

    Clomipramine hydrochloride CLINICAL USE Depressive illness Phobic and obsessional states<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3852","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3852","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3852"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3852\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3852"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3852"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3852"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}